FDA Clearance Tracker · K160990
Nova Max Uric Acid Monitoring System
Last checked: Nov 20, 2026Latest source record: Apr 11, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Apr 11, 2017
Substantially Equivalent
Time to decision
368 days
Received Apr 8, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class I
The decision
- FDA number
- K160990
- Device name
- Nova Max Uric Acid Monitoring System
- Applicant
- Nova Biomedical Corporation
- Applicant location
- Walham, MA
- Received
- Apr 8, 2016
- Decided
- Apr 11, 2017
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class I
- Regulation
- 21 CFR 862.1775
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code PTC (Uric Acid Test System For At Home Prescription Use).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K160990
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Nova Biomedical Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K251281 · Decided Jan 21, 2026 · 272 days after receipt
Device type: Creatinine Test System For At Home Prescription Use (SHB) · Laboratory Medicine & Pathology
K252206 · Decided Jan 9, 2026 · 179 days after receipt
Device type: Alkaline Picrate, Colorimetry, Creatinine (CGX) · Laboratory Medicine & Pathology
K221326 · Decided Nov 22, 2024 · 931 days after receipt
Device type: Assay, Glycosylated Hemoglobin (LCP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.